Journal français d'ophtalmologie
-
Multicenter Study
[Ocular and neuro-ophthalmic manifestations of sarcoidosis: retrospective study of 30 cases].
The purpose of this study was to describe the diagnostic strategy and therapeutic approach when sarcoidosis of the visual pathways is suspected, by way of a descriptive study of sarcoidosis patients in the ophthalmology services in Tours, Rennes and Angers. ⋯ Positive diagnosis of sarcoidosis requires a careful history and clinical examination, ancillary testing, and collaboration among several medical specialties. Normal angiotensin-converting enzyme levels do not rule out the diagnosis, since in our series, they were normal in almost half the cases. The tests with highest sensitivity included: a negative tuberculin skin test (100%), an elevated CD4/CD8 ratio in the BALF (100%), radiographic evidence of sarcoidosis on chest CT (79%) and brain MRI (80%). Other factors contributing to the diagnosis were: female gender (83%), age over 40 (67%), arthralgia (41%), asthenia (50%), vitritis (67%) and multifocal choroiditis (30%). In our study, treatment with corticosteroids resulted in significant improvement in over 80% of patients.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
Carteolol is a beta-adrenoceptor antagonist with intrinsic sympathomimetic activity. Used topically to reduce intraocular pressure, it is typically applied twice daily. In an effort to provide a once-daily dosing regimen, carteolol was formulated with 1% alginic acid. Sodium alginate is a natural polymer product with bioadhesive properties providing increased corneal contact time and a better carteolol penetration through the cornea. The objective of this study was to evaluate the efficacy and safety of long-acting 1% carteolol alginate solution compared to standard 1% carteolol solution. ⋯ The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety. This efficacy wasy was verified at 9 AM (24 hours after the last drop of long-acting carteolol or 12 hours after that of standard carteolol) and at 11 AM (2 hours after the morning drop). The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.
-
Multicenter Study
[Activity and epidemiology in an ophthalmological emergency center].
To investigate the numbers and characteristics of patients with ophthalmological emergencies presenting at a general hospital. ⋯ There is a real need for ophthalmic emergency services in general hospitals. Benign pathologies not needing diagnosis and adapted treatment were not noted in our study. The cheapest and most efficient way to diagnose these ophthalmic emergencies appeared to be the ophthalmological emergency center with a senior ophthalmologist, according to the regional health organization.